Products, Major Customers and Concentrations of Credit Risks

Our primary product groups are infusion therapy, critical care and oncology. The breakdown by market segment are as follows (in millions):



	Year Ended December 31,
	2016		2015		2014
Infusion therapy	$	272.6	$	244.7	$	216.3
Critical care	53.6		54.3		55.0
Oncology	52.3		41.5		36.7
Other	0.9		1.2		1.3
	$	379.4	$	341.7	$	309.3

We sell products worldwide, on credit terms on an unsecured basis, as an OEM supplier, to independent medical supply distributors and directly to the end customer. The manufacturers and distributors, in turn, sell our products to healthcare providers. For the years ended December 31, 2016, 2015 and 2014, we had worldwide sales to one manufacturer, Pfizer, of 30%, 36% and 36%, respectively, of consolidated revenue. As of December 31, 2016, and 2015, we had accounts receivable from Pfizer of 23% and 40%, respectively, of consolidated accounts receivable.

In February 2017, we completed the acquisition of Pfizer's HIS business, which we acquired in part to protect against the significant earnings exposure indicated above (see Note 3: Acquisitions and Strategic Transaction Expenses).

Domestic sales accounted for 70%, 71% and 69% of total revenue in 2016, 2015 and 2014, respectively. International sales, which are determined by the destination of the product shipment, accounted for 30%, 29% and 31% of total revenue in 2016, 2015 and 2014, respectively.

The table below presents our gross long-lived assets, consisting of property, plant and equipment, by country (in thousands):



	As of December 31,
	2016		2015
Mexico	$	57,971	53,462
Slovakia⁽¹⁾	—		5,480
Italy	4,320		4,418
Germany	686		671
Netherlands	278		49
Australia	41		35
France	2		—
Total foreign	$	63,298	$	64,115
United States	180,657		158,933
Worldwide total	$	243,955	$	223,048

____________________________

⁽¹⁾The decrease in Slovakia long-lived assets relates to the 2016 closure of those facilities and the increase in Mexico is due to expansion to absorb the production capacity of the closed Slovakian facilities.